| It is phosphorylated in the body to corresponding nucleotide, which inhibits DNA repair. Cytorabine is cell cycle specific and acts primarly during S phase. Its main use is to induce remission in acute leukemia.
| Composition : | 100mg/1ml, 500mg/5ml, 1000mg/10ml | | Indications : | Acute leukemias, lymphosarcomas. | | Dosage: | 3-6 mg/Kg body wt. i.v daily in 2 divided doses for 5-10 days. | | Conraindications: | Hypersensitivity, Pregnancy. | | Special Precautions : | Hepatic impairment.
Paediatrics : Indicated in certain leukemia, under strict supervision.
Pregnancy : Safety not established
Lactation : Safety not established
Elderly : Use with caution | | Side- Effect : | Bone marrow suppression. G.I.T disturbances. | | Drug Interaction : | Potentiates bone marrow depression with radiotheraphy and other myelotoxic drugs. Reduces plasma concentration of digoxin,antagonizes gentamycin. Decreased efficacy of flurocytosine. | | Purity : | Not less than 99%. |
|
© Health Biotech Limited. All Rights Reserved (Terms of Use)
